logo-loader
LON:MTFB

Motif Bio PLC

Receive alerts
Market:
LON
Market Cap:
£8.15 m
Price
£0.02
Change
-4.99%
52 weeks high
44.90
52 weeks low
2.00

Viewing results 1-25 of 169

RNS

Second Price Monitoring Extn

3 days, 4 hours ago
RNS

Price Monitoring Extension

3 days, 4 hours ago
RNS

Holding(s) in Company

2 weeks, 2 days ago
Health

Motif Bio lender supportive ahead of key meeting with American regulator

Hercules Capital has pushed out the amortisation date on Motif's loan...

2 weeks, 4 days ago
Health

Motif Bio prepares for new iclaprim study

Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections ...

4 weeks, 1 day ago
Health

Motif Bio assessing lead drug iclaprim potential as a combatant for the life-threatening infection listeria

Partner JMI Laboratories will use pre-clinical services provided by National Institute of Allergy and Infectious Diseases, to assess the antibiotic...

on 19/8/19
Tech

Amphion Innovations keen to hold onto Polarean Imaging stake

Amphion Innovations provides “concentrated but well-managed portfolio” in high growth sectors...

on 13/8/19
Tech

Amphion Innovations keen to hold onto Polarean Imaging stake

Amphion Innovations provides “concentrated but well-managed portfolio” in high growth sectors...

on 13/8/19
Health

Motif Bio's lender postpone's loan amortisation date by one month

Hercules Capital made this change in support of Motif Bio managing its cash runway as it advances its pipeline expansion strategy....

on 1/8/19
Health

Motif Bio to meet US regulator on September 19 to discuss trial design

The Food & Drug Administration in an earlier discussion urged Motif to carry out a further trial to allay concerns over liver toxicity...

on 26/7/19
Health

Motif Bio PLC requests meeting with US regulator to discuss trial design

It has made the request after being encouraged by the US Food & Drug Administration to carry out further work on flagship drug iclaprim ...

on 15/7/19
Tech

Amphion Innovations delays publication of 2018 accounts

“The reason for the delay is continuing work with the company's auditors in relation to the going concern status of the company”...

on 27/6/19
Health

Motif Bio presents new iclaprim data at industry conference in California

Motif presented three new posters, tackling iclaprim’s dosage, the diversity of patients who have taken part in clinical trials, and the antibiotic’s ability to fight off drug-resistant bacteria...

on 24/6/19
Health

Motif Bio says US drugs regulator has encouraged it to carry out further study on antibiotic

The guidance was contained in minutes from a meeting with the Food & Drug Administration in early May ...

on 6/6/19
Health

Motif Bio boss “very confident” in potential of flagship antibiotic

Motif Bio is working with US regulators as it tries to get approval for iclaprim, while the antibiotic has also shown potential as a treatment for certain lung and eye infections...

on 22/5/19
Health

Motif Bio teams up with German university to see if iclaprim can help patients with rare eye disease

Researchers at the Otto-von-Guericke University Magdeburg are to carry out a series of lab tests to evaluate iclaprim as a possible treatment for toxoplasma chorioretinitis...

on 22/5/19
Health

Motif Bio to present three iclaprim posters at industry conference in San Francisco next month

The three posters will contain data on Motif Bio’s lead product, a next-generation antibiotic...

on 21/5/19